PEPTIDEPEDIA.US
All peptides
Cellular Energy & LongevityGrade A

NAD+

Compound class: Metabolic Cofactor

Also known as Nicotinamide Adenine Dinucleotide

An essential cellular redox coenzyme involved in energy metabolism, mitochondrial function, enzymatic signaling, and DNA-repair pathways.

Regulatory status
Metabolic cofactor — regulatory status depends on route and formulation

NAD+ is not a peptide. Intravenous NAD+ is not an FDA-approved anti-aging therapy; oral NAD precursors such as NR and NMN are regulated separately as dietary or investigational products.

Half-life
No reliable universal human half-life established

Human IV studies report rapid changes in plasma NAD+ and metabolite profiles; values differ by infusion rate, assay, and metabolite measured.

Route
Intravenous infusion; oral precursors (NR, NMN) studied separately

IV NAD+ administration is investigational and should occur only under qualified medical supervision.

Evidence
Multiple randomized controlled trials in humans

Mechanism of action

NAD+ cycles with NADH to carry electrons through glycolysis, TCA-cycle-linked metabolism, and oxidative phosphorylation, supporting ATP production. NAD+ is also consumed as a substrate by sirtuins, PARPs, and CD38, linking it to DNA-repair signaling, transcriptional regulation, and cellular stress responses.

NAD+ ↔ NADHCellular redox metabolismATP productionSirtuins / PARPsCell signaling & DNA repair

Studied and reported uses

  • Cellular energy metabolism

    NAD+ is an essential coenzyme in cellular redox reactions required for substrate oxidation and ATP generation.

  • Mitochondrial biology

    The NAD+/NADH ratio is central to mitochondrial energy metabolism and electron-transport function.

  • Aging biology

    Age-associated changes in NAD metabolism are a major area of scientific research, including in animal and human cohort studies.

  • NAD-boosting strategies

    Human research has evaluated NAD precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which reliably raise blood NAD metabolites; clinical outcome effects remain under study.

  • Intravenous NAD+ research

    Direct IV NAD+ has been investigated in smaller human pharmacokinetic and tolerability studies. These findings are separate from NR/NMN evidence.

Dosing information

Clinical research informationNo established clinical dosing exists for intravenous NAD+ as a therapy; protocols used in clinics are not standardized or approved.
Precursor studiesHuman trials of NR and NMN used defined oral daily amounts (dose used in those studies, not a recommended dose).

Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.

Published research has used different experimental protocols depending on the compound, formulation, route, indication and study design. These study protocols should not be interpreted as established clinical dosing recommendations.

Important pharmacology

Precursor evidence is not IV evidence

Clinical findings from oral NR or NMN should not be transferred onto intravenous NAD+. The routes, metabolism, and evidence bases are distinct and must be evaluated separately.

Metabolism and disposition

Human IV research has measured plasma NAD+ and its metabolites, indicating rapid metabolism into related products. A universal human half-life is not reliably established.

Enzymatic consumption

Sirtuins, PARPs, and CD38 continuously consume NAD+, so cellular NAD+ status reflects synthesis, salvage, and consumption rather than intake alone.

Side effects

  • Infusion-rate-related chest tightness
  • Nausea
  • Flushing
  • Headache
  • Cramping during rapid infusion
  • General IV risks: infection, phlebitis, extravasation

Reported effects should be separated into compound-related effects, infusion-rate-related effects (which often resolve when the rate is reduced), and general risks of intravenous access. Claims that IV NAD+ reverses aging, detoxifies the body, cures addiction, treats fatigue, or raises ATP in every patient are not supported by the cited evidence.

Research evidence

IV NAD+ pharmacokinetics in humans

Human Clinical Trial (small): measured plasma NAD+ and metabolite changes during and after infusion.

Nicotinamide riboside trials

Human RCT: oral NR reliably increases blood NAD+ metabolites; clinical outcome benefits are inconsistent across trials.

NMN trials

Human RCT: randomized studies report increased NAD metabolites with variable functional outcomes.

NAD decline with age

Human Observational / Animal: tissue and blood NAD levels decline with age in multiple models and cohorts.

Sirtuin and PARP biology

Mechanistic: NAD+ availability regulates sirtuin and PARP activity in DNA repair and stress signaling.

Scientific references

  • A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6-hour intravenous infusion of NAD+

    Grant R, et al. · Frontiers in Aging Neuroscience · 2019

    Frontiers in Aging Neuroscience (PubMed-indexed)

    Human Clinical TrialPubMed

  • Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

    Martens CR, et al. · Nature Communications · 2018

    Nature Communications (PubMed-indexed)

    Human RCTPubMed

  • Nicotinamide mononucleotide supplementation in humans: randomized controlled studies

    PubMed-indexed randomized trials of NMN

    Human RCTPubMed

  • NAD+ metabolism and its roles in cellular processes during ageing

    Covarrubias AJ, et al. · 2021

    Nature Reviews Molecular Cell Biology (PubMed-indexed review)

    ReviewPubMed

  • NAD+ in DNA repair and sirtuin signaling

    PubMed-indexed mechanistic literature on PARPs and sirtuins

    MechanisticPubMed

  • Registered clinical studies of intravenous NAD+

    ClinicalTrials.gov registry records

    Human Clinical TrialClinicalTrials.gov